NCT00660387/LCIG  Levodopa-Carbidopa intestinal gel (LCIG), administered by continuous intra-intestinal infusion (Duodopa®)  - Change from baseline to week 12 in average daily normalized off-time- Change from baseline in average daily normalized on-time without troublesome dyskinesia at week 12  Reduced OFF-time after 12 weeks by 4 h compared to baseline and 1.91 h compared to standard oral formulation.Reduced OFF time by 4.04 h in LDIG group vs. 2.14 h in the standard oral formulation group (p = 0.0015)Increase in on-time without troublesome dyskinesia (TSD)  Approved by FDA/EUNo difference in UPDRS motor scores